IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence ...

The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Fintel reports that on April 25, 2025, HSBC downgraded their outlook for IQVIA Holdings (NYSE:IQV) from Buy to Hold. Analyst ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $227.67, ...

With a market cap of $25.4 billion, IQVIA Holdings Inc. (IQV) provides clinical research services, commercial insights, and ...

The stock's rise snapped a four-day losing streak.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm ...

HSBC analyst Sidharth Sahoo downgraded Iqvia (IQV) to Hold from Buy with a price target of $160, down from $260. The firm adjusted ratings in ...

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

Comac Medical, a full-service contract research organization (CRO) based in Bulgaria, has announced major leadership changes ...

The life sciences innovation ecosystem continued to evolve and expand in 2024 as the industry continued to adapt to a complex ...